Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
| 対象疾患 | Lupus Erythematosus, Lupus Nephritis |
|---|---|
| 相 | 第1相 |
| スポンサー | Biocon Limited |
| ステータス | 完了 |
| 参加者数 | 52 名 |
| 介入（薬剤） | Itolizumab [Bmab 600] |
| 開始日 | 2019年10月1日 |
| 完了日 | 2023年11月16日 |
| 結果公開日 | 2025年4月18日 |
概要
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
Number of Treatment Emergent Adverse Events
| EQ001 Type A Cohort (0.4mg/kg) | 0 Participants |
|---|---|
| EQ001 for Type B Cohort | 17 Participants |
| EQ001 Type A Cohort (0.8mg/kg) | 2 Participants |
| EQ001 Type A Cohort (1.6mg/kg) | 4 Participants |
| EQ001 Type A Cohort (2.4mg/kg) | 3 Participants |
| EQ001 Type A Cohort (3.2mg/kg) | 8 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health